Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760845 | 0.83 | ALDH1A1 (0.47) | GRIN1GRIN2BCCR5CCR3GAA | |
| SCHEMBL1760952 | 0.80 | LPL (0.49) | CCR5CCR3 | |
| SCHEMBL4775057 | 0.77 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL5245652 | 0.76 | CYP2D6 (0.47) | SMN1; SMN2MEN1KMT2ACCR3HPGD | |
| SCHEMBL4958207 | 0.76 | MEN1 (0.65) | SMN1; SMN2MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL17966723 | 0.75 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL13279147 | 0.74 | HRH4 (0.61) | SMN1; SMN2MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL13873202 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1KMT2ACCR3 | |
| SCHEMBL12929417 | 0.73 | HTR1A (0.51) | SMN1; SMN2MEN1KMT2AOPRM1 | |
| SCHEMBL1443441 | 0.73 | HRH3 (0.47) | SMN1; SMN2GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-2051977-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 | Amgen Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| EP-1778675-A1 | CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF | Cylene Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015150-A1 | CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF | CYLENE PHARMACEUTICALS (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | CYLENE PHARMACEUTICALS | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | SMN1; SMN2 3710/4885MEN1 1658/4885KMT2A 2389/4885 |
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | PIN1, HPD, DHPS | SMN1; SMN2 4589/4885MEN1 2391/4885KMT2A 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.